BARCELONA (Spain), July 31, 2026

REIG JOFRE RETURNS TO PROFITABLE GROWTH, WITH EBITDA OF €18 MILLION, UP 27% IN THE FIRST HALF

H1 2026 Key Financial Highlights

→ **Revenue:** €168.5 million, up 1% versus H1 2025, despite the temporary impact of the disruption to Forté Pharma's supply chain in France and Belgium, which was resolved in June.

→ **Gross profit:** €100.1 million, €0.4 million above H1 2025, representing a gross margin of 59.4%.

→ **Consolidated EBITDA:** €17.9 million, up 27% versus H1 2025, with the EBITDA margin improving to 10.7%.

→ **Consolidated net income:** €3.4 million, up 126% versus H1 2025.

→ **Net financial debt:** €117.7 million, with a net financial debt-to-EBITDA ratio of 3.4x, including debt allocated to new biotechnology investments.

→ **Operating milestones:** regulatory approval and start-up of the new antibiotics production line in Toledo; normalization of Forté Pharma's supply chain in France and Belgium; continued growth of dalbavancin in Europe; and progress in the construction of Leanbio's new GMP facility and in the development of Syna Therapeutics' biosimilar.

REIG JOFRE, (BME:RJF), closed the first half of 2026 with revenue of €168.5 million, up 1% compared with the same period of the previous year, and EBITDA of €17.9 million, representing growth of 27%.

The EBITDA margin improved to 10.7%, reflecting a clear recovery compared with the first half of 2025. This performance was supported by the commercial momentum of prescription solutions in the osteoarticular and dermatology areas, as well as the initial recovery of the antibiotics business.

Consolidated net income reached €3.4 million, up 126% compared with the same period of the previous year, despite higher financial expenses and an asset impairment charge whose recovery is expected during the year as insurance proceeds are collected.

During the second quarter, REIG JOFRE achieved significant milestones across its key business and industrial projects. At the end of June, the company obtained regulatory approval for the new penicillin-based injectable antibiotics production line in Toledo, a project launched in early 2024, and began commercial production. Forté Pharma's supply chain in France and Belgium was also fully restored, while the performance of dalbavancin, the company's latest launch of a non-penicillin injectable antibiotic in Europe, continued to gain traction.

Strategic Repositioning of the Antibiotics Business at the Toledo Facility: Technology, Efficiency and Competitiveness to Support Future Growth

REIG JOFRE continues to advance a strategic repositioning of its antibiotics business, aimed at driving profitable and sustainable growth through the optimization of its portfolio and production lines, with operational excellence and quality as competitive advantages.

The new line upgrades the production of injectable beta-lactam antibiotics through state-of-the-art facilities and equipment, greater automation, cost optimization, and technologies aligned with the latest European Good Manufacturing Practice (GMP) standards. Once operational, it is expected to increase annual production capacity for injectable penicillin-based products by 50% over the coming years, enhance productivity, provide the facility with greater operating flexibility, and strengthen the competitiveness of the supply of essential antibiotics across several European countries.

Following regulatory approval from the health authorities at the end of June, the new antibiotics production line in Toledo began start-up activities and the release of its first batches. The increase in production capacity supported a 16% rise in antibiotics sales in the second quarter compared with the same period of 2025. The new line is expected to make a progressively increasing contribution to sales beginning in the second half of 2026.

Continued Growth of dalbavancin in Europe

Sales in the injectables portfolio remained stable during the first half, supported by the strong performance of dalbavancin, the latest addition to REIG JOFRE's hospital portfolio. This antibiotic, indicated for the hospital treatment of acute bacterial skin and skin structure infections, is manufactured at the Barcelona facility and is already marketed in nine European countries through both the Group's subsidiaries and licensing agreements.

Growth in dalbavancin offset the temporary reduction in production capacity resulting from the adaptation of one of the Barcelona production lines to the requirements of Annex 1 of the European GMP guidelines. Completion of this adaptation is expected during the second half of 2026.

Dalbavancin continues to strengthen REIG JOFRE's international presence in the hospital segment and its commitment to expanding access across Europe to essential, first-line anti-infective medicines.

Progress of the Biotechnology Platform

REIG JOFRE continued to advance the integration of its biotechnology capabilities during the first half of the year.

Leanbio made progress on the construction of its GMP facility for the manufacture of biotechnology active pharmaceutical ingredients, while Syna Therapeutics continued the clinical development of its biosimilar during 2026. Total investment in biotechnology amounted to €10 million in the first half.

Normalization of Forté Pharma's Supply Chain

Forté Pharma's supply chain in France and Belgium, which had been affected by a fire since mid-March, was fully restored in June.

The disruption had a temporary impact on sales between March and May. Following the normalization of supply, Forté Pharma is preparing its fall campaign with preventive health products focused on areas including energy and sleep. The brand also continues to strengthen its multispecialty positioning in segments such as oral hydration and women's health.

Financial Performance

REIG JOFRE's revenue reached €168.5 million in the first half of 2026, compared with €167.4 million in the same period of the previous year.

Gross profit amounted to €100.1 million, €0.4 million above H1 2025, representing 59.4% of revenue. Grant income related to the EMINTECH project totaled €3.5 million, equivalent to 50% of the expenses associated with the project.

Capitalized internal development costs amounted to €9 million, mainly related to progress on Syna Therapeutics' biosimilar project.

Employee compensation expenses increased by 12% compared with the previous year, primarily due to the addition of Leanbio, S.L. and Syna Therapeutics, S.L. employees to the Group's workforce.

EBITDA reached €17.9 million, compared with €14.2 million in the first half of 2025, representing an increase of 27%. The EBITDA margin improved to 10.7%. Operating profit amounted to €3.8 million, up 104% compared with the same period of the previous year. Consolidated net income reached €3.4 million, compared with €1.5 million in H1 2025, representing growth of 126%.

Net financial debt amounted to €117.7 million, and the net financial debt-to-EBITDA ratio stood at 3.4x. Gross financial debt totaled €131 million, of which €105 million related to the business excluding Syna Therapeutics and Leanbio, and €26 million to these two biotechnology companies.

Industrial and Technology Investments

Property, plant and equipment and other non-current assets reached €206 million at the end of the first half, compared with €199 million at year-end 2025.

Investments comprised €7.7 million in industrial projects, €9.0 million in R&D projects, €1.4 million in digital initiatives, and €2.8 million in right-of-use assets.

Industrial investment focused on the construction of Leanbio's new GMP facility; completion of the adaptation of Barcelona Line 2 to the new Annex 1 GMP requirements, a project launched in 2024 and expected to be completed in the second half of 2026; and the start-up of the new antibiotics production line in Toledo.

Performance by Business Unit

→ **Pharmaceutical Technologies,** specializing in injectable hospital medicines and antibiotics, generated sales of €69 million, down 2% compared with the first half of 2025. Following the regulatory approval received at the end of June, the new antibiotics production line in Toledo began start-up activities and the release of its first batches. Antibiotics sales grew by 16% in the second quarter compared with Q2 2025. Injectables sales remained stable, supported by the positive performance of dalbavancin, which offset the temporary reduction in production capacity associated with the adaptation of Barcelona Line 2. Advanced CDMO services accounted for 27% of the division's sales.

- **Specialty Pharmacare,** specializing in prescription medicines and healthcare products in dermatology and osteoarticular health, the business unit generated sales of €67 million, up 14% compared with the first half of 2025. The osteoarticular area grew by 23%, driven by Droglican® and Cartexan® in Poland, where sales increased by 57%. In dermatology, Dexulac® grew by 19% in Spain, and direct sales of Vincobiosis® were recorded in five countries. These results partially offset the decline in other, more mature and lower-margin dermatology franchises. Specialty Pharmacare's international sales increased by 19%, supported by CDMO services in Sweden for Parkinson's disease treatments, which grew by 79%, and by the performance of the osteoarticular business in Poland.

- **Consumer Healthcare,** specializing in non-prescription healthcare products for wellness, prevention and pharmacist recommendation under the Forté Pharma and Reig Jofre brands, with an integrated offering covering sleep, stress, energy, probiotics and over-the-counter ear, nose and throat products, generated sales of €32 million, down 17% compared with the first half of 2025. This decline was mainly due to the temporary disruption to Forté Pharma's supply chain in France and Belgium. Supply was fully restored in June, and Forté Pharma is preparing its fall campaign with products focused on various preventive health areas. In the OTC business, adjustments in the ear, nose and throat and nasal saline categories were partially offset by growth in Otocerum®, whose sales increased by 8%.



International Expansion

A total of 55% of the Group's sales were generated outside Spain.

The Group's eight European subsidiaries contributed €101 million, equivalent to 60% of total sales. Licensing and distribution agreements for proprietary products generated €37 million, or 22% of the total, while advanced CDMO services contributed €30 million, representing 18% of sales.

Direct sales through the Group's European subsidiaries increased by 2% during the first half.



Receive the **latest news** from listed company REIG JOFRE by registering in its [subscription center]

About REIG JOFRE

REIG JOFRE is a pan-European pharmaceutical company with almost a century of history, whose purpose is to universalize the science that matters. It develops, manufactures and markets essential healthcare solutions that support people throughout all stages of life — from daily care and prevention to the most critical medical care — applying scientific rigor and a holistic vision to generate a tangible impact on patients and healthcare systems. The Group is organized into three business units — Pharmaceutical Technologies (hospital injectables and antibiotics), Specialty Pharmacare (dermatology and musculoskeletal health) and Consumer Healthcare (over-the-counter products for wellbeing and prevention, with Forté Pharma) — a structure that enhances synergies between technology, innovation and international expansion. It also acts as an end-to-end CDMO partner, integrating drug substance and drug products to simplify development and manufacturing and accelerate patient access. With more than 1,400 professionals, a direct presence in Europe through eight commercial offices in Spain, Portugal, France, Sweden, the United Kingdom, Belgium, Poland and the Czech Republic, and a broad partner network through licensing and distribution agreements, its solutions reach more than 70 countries. In 2025, it recorded revenue of €331.1 million and EBITDA of €30.4 million. The company is listed on the Spanish Continuous Market under the ticker RJF.

INCOME STATEMENT *(thousand euros)*	30/06/2026	30/06/2025	V%
Turnover	**168.455**	**167.401**	**1%**
Cost of Sales	(68.349)	(67.685)	1%
Gross margin	100.106	99.715	0%
Work carried out for fixed assets	8.951	1.831	389%
Other operating income	3.507	232	1414%
Personnel expenses	(52.320)	(46.624)	12%
Other operating expenses	(42.295)	(40.980)	3%
EBITDA	**17.949**	**14.174**	**27%**
Depreciation and amortization	(12.974)	(12.411)	5%
Govern. grants for non-financial assets and others	535	126	323%
Impairment and results on disposals	(1.667)	(7)	
Operating income	3.843	1.882	104%
Financial result	(1.246)	(277)	349%
Results from entities accounted by the equity method	-	(260)	(100%)
Profit before taxes	2.599	1.345	93%
Income tax	833	173	380%
NET RESULT	**3.432**	**1.518**	**126%**

BALANCE SHEET *(thousand euros)*	30/06/2026	31/12/2025
Goodwill	26.509	26.495
Other intangible assets	75.400	69.581
Property, plant and equipment	130.728	129.501
Non-current financial assets measured at fair value	882	887
Other non-current financial assets	758	603
Deferred tax assets	13.435	12.185
TOTAL NON-CURRENT ASSETS	**247.712**	**239.252**
Inventories	74.788	61.612
Trade and other receivables	70.894	65.285
Current tax assets	5.277	7.006
Other current financial assets	1.536	6.506
Other current assets	6.918	4.525
Cash and cash equivalents	13.574	10.500
TOTAL CURRENT ASSETS	**172.987**	**155.434**
TOTAL ASSETS	**420.699**	**394.686**

BALANCE SHEET *(thousand euros)*	30/06/2026	31/12/2025
Share capital	41.442	41.110
Share Premium	19.000	19.000
Treasury shares	(2.858)	(2.836)
Reserves	162.157	156.880
Own equity instruments	174	174
Profit attributable to the parent company	3.095	5.021
Exchange differences	(2.008)	(1.389)
Other comprehensive income	112	112
Equity attributable to parent company	**221.114**	**218.072**
Non-controlling interests	2.379	2.378
TOTAL EQUITY	**223.493**	**220.450**
Capital grants	6.153	5.863
Provisions	500	500
Financial liabilities with credit institutions	53.312	43.133
Lease liabilities	15.386	15.333
Other financial liabilities	5.034	5.969
Deferred tax liabilities	2.362	2.319
TOTAL NON-CURRENT LIABILITIES	**82.747**	**73.117**
Provisions	64	0
Financial liabilities with credit institutions	45.811	27.302
Lease liabilities	5.068	5.736
Other financial liabilities	6.667	14.137
Liabilities from contracts with customers	1.328	2.705
Trade and other payables	50.188	45.775
Current tax liabilities	5.255	5.315
Other current liabilities	78	149
TOTAL CURRENT LIABILITIES	**114.459**	**101.119**
TOTAL EQUITY AND LIABILITIES	**420.699**	**394.686**